27 May 2024 --- A US study reveals a 594% increase from 2020 to 2023 in the monthly number of adolescents and young adults using glucagon-like peptide-1 (GLP-1) receptor agonist medications, such as Wegovy and Ozempic. The use grew fastest among female youth. GLP-1 use increased by 588% among female adolescents (aged 12–17) and 504% among male adolescents. In young adults (aged 18–25), the number of female users of the medications increased by 659%, compared to 481% for male young adults.